Infusionstherapie und Transfusionsmedizin最新文献

{"title":"[Flow cytometry analysis of CD34 expressing hematopoietic cells in blood and cytapheresis products].","authors":"K Gutensohn, S Serke, V Kretschmer","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13632,"journal":{"name":"Infusionstherapie und Transfusionsmedizin","volume":"23 Suppl 2 ","pages":"1-23"},"PeriodicalIF":0.0,"publicationDate":"1996-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19889037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How accurate is serologic testing of plasma pools for hepatitis B virus surface antigen, anti-human immunodeficiency virus 1 and 2, and anti-hepatitis C virus?","authors":"H Rabenau,&nbsp;R Schütz,&nbsp;A Berger,&nbsp;H W Doerr,&nbsp;B Weber","doi":"10.1159/000223281","DOIUrl":"https://doi.org/10.1159/000223281","url":null,"abstract":"<p><strong>Objective: </strong>The European pharmacopeia prescribes that, during the manufacture of blood derivates, the first homogeneous pool of plasma (for example, after removal of cryoprecipitate) must be tested for hepatitis B virus surface antigen (HBsAg), for hepatitis C virus (HCV) antibodies and for human immunodeficiency virus (HIV) antibodies using test methods of suitable sensitivity and specificity, in order to reduce the residual risk of infection originating from blood products. The present study was performed to verify if commercially available immunoassays, which are licensed for the screening of single serum and plasma samples, are suitable for the determination of HBsAg, anti-HCV, and anti-HIV in plasma pools.</p><p><strong>Design: </strong>Plasma tools originating from different countries were spiked with HBsAg- and anti-HCV-positive standards (National Institut für Biological Standards, Hertfordshire, UK) and anti-HIV-positive serum. For the determination of HBsAg with and without immune complex dissociation (ICD), anti-HCV and anti-HIV antibodies the Abbott (Delkenheim, Germany) IMx system was used.</p><p><strong>Results: </strong>In contrast to the testing for anti-HIV and anti-HCV, the detection of HBsAg (0.125 IU/ml detection limit) was influenced by the presence of anti-HBs in plasma pools. Statistically significant differences could be observed between anti-HBs-positive plasma pools and anti-HBs-negative serum samples spiked with HBsAg. The kinetics of HBsAg-anti-HBs complex formation showed that in a plasma pool with a high anti-HBs (329.4 IU/ml) concentration HBsAg was not detectable after 5 h of incubation. After ICD, HBsAg was still detectable in the pool with high anti-HBs content. Anti-HIV antibodies could be detected up to a dilution of 1/480,000, anti-HCV up to a dilution of 1/80, both in a spiked negative serum. Overall, the divergences between spiked plasma and serum were relatively low for anti-HCV and anti-HIV detection.</p><p><strong>Conclusion: </strong>The Abbott IMx assay permits a highly sensitive detection of HBsAg (after ICD or immediately after thawing of anti-HBs-positive plasma pools), anti-HCV, and anti-HIV in plasma pools. However, in case of a contamination with donations originating from individuals with acute HBV, HIV, or HCV infection or with a poor humoral immune response, serologic testing for HBsAg, anti-HIV, and anti-HCV may fail to detect potentially infectious plasma pools.</p>","PeriodicalId":13632,"journal":{"name":"Infusionstherapie und Transfusionsmedizin","volume":"23 3","pages":"124-30"},"PeriodicalIF":0.0,"publicationDate":"1996-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000223281","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19753723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applications of hematopoietic stem cells and gene transfer.","authors":"R Huss","doi":"10.1159/000223285","DOIUrl":"https://doi.org/10.1159/000223285","url":null,"abstract":"<p><strong>Objective: </strong>In this review, the hematopoietic stem cell is defined and the change of this definition over the past decades is elucidated. Besides we discuss how the applications of stem cell transplantation have changed in the same period of time. In addition to the biology of hematopoietic stem cells, the most recent applications in gene transfer and gene therapy will be discussed.</p><p><strong>Data sources: </strong>Review of the literature and results of studies performed at the Fred Hutchison Cancer Research Center in Seattle, USA.</p><p><strong>Selection criteria: </strong>Peer review journals and papers relevant to the topic.</p><p><strong>Results: </strong>Based on the initial radiation experiments in mice, the hematopoietic stem cell was defined by its biological properties and later by the expression of certain surface antigens, as well as the absence of lineage-specific markers. Quite recently, more and more evidence has emerged that hematopoietic stem cells can be isolated from peripheral blood and that there might be a common progenitor of hematopoiesis and the marrow microenvironment. Hematopoietic stem cells are also a useful aid for gene therapy in a broader range of immunodeficiencies and metabolic disorders.</p><p><strong>Conclusions: </strong>Peripheral blood stem cells transplantation and gene therapy will be useful tools to treat a broader spectrum of diseases using uncommitted very early progenitor cells isolated from peripheral blood.</p>","PeriodicalId":13632,"journal":{"name":"Infusionstherapie und Transfusionsmedizin","volume":"23 3","pages":"147-60"},"PeriodicalIF":0.0,"publicationDate":"1996-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000223285","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19753725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roundtable of Experts in Surgery Blood Management--consensus statement.","authors":"K Messmer","doi":"10.1159/000223284","DOIUrl":"https://doi.org/10.1159/000223284","url":null,"abstract":"<p><strong>Unlabelled: </strong>A Roundtable of Experts in Surgery Blood Management was held 7 to 9 April 1995, in Vienna, where all the available published and unpublished epoetin alfa clinical data was thoroughly discussed and where the following CONSENSUS STATEMENT was developed to give the clinician some practical guidelines for the administration of epoetin alfa in elective surgery patients.</p><p><strong>Consensus statement: </strong>For elective surgery patients it is important to facilitate, via blood conservation methods, the elimination or reduction of exposure to allogeneic blood transfusion and its associated risks. Adjunctive use of epoetin alpha therapy in specific patients is one method to accomplish this goal. Patients with small body size, predicted low blood volume (< or = 51), and/or a hematocrit too low to be enrolled in or to complete their prescribed ABD (autologous blood donation) program especially benefit from epoetin alfa therapy. Generally, epoetin alfa therapy is well tolerated, with an acceptable risk-to-benefit ratio.</p>","PeriodicalId":13632,"journal":{"name":"Infusionstherapie und Transfusionsmedizin","volume":"23 3","pages":"143-6"},"PeriodicalIF":0.0,"publicationDate":"1996-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000223284","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19753724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Inquiry by Mrs. U. Engelhardt. Directed blood donation].","authors":"U Engelhardt","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13632,"journal":{"name":"Infusionstherapie und Transfusionsmedizin","volume":"23 2","pages":"99-101"},"PeriodicalIF":0.0,"publicationDate":"1996-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19749074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Patient education about autologous blood donation].","authors":"W Weissauer","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13632,"journal":{"name":"Infusionstherapie und Transfusionsmedizin","volume":"23 2","pages":"66"},"PeriodicalIF":0.0,"publicationDate":"1996-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19750391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decrease of fibronectin following repeated infusion of highly substituted hydroxyethyl starch.","authors":"J Treib,&nbsp;A Haass,&nbsp;G Pindur,&nbsp;M T Grauer,&nbsp;E Wenzel,&nbsp;K Schimrigk","doi":"10.1159/000223261","DOIUrl":"https://doi.org/10.1159/000223261","url":null,"abstract":"<p><strong>Objective: </strong>Fibronectin (Fn) plays an important part in unspecific defense mechanisms because of its ability to mediate the binding of foreign-body particles, bacteria, collagen, and other macromolecules to phagocytising cells of the reticulo-endothelial system (RES). The aim of the present study was to examine the effect of a 10-day hemodilution therapy on Fn concentration in humans.</p><p><strong>Design: </strong>The patients were randomized and treated with either 10% hydroxyethyl starch (HES) 200/0.62 or 6% HES 200/0.62.</p><p><strong>Setting: </strong>Neurology department of an university clinic.</p><p><strong>Patients: </strong>We examined 12 patients with cerebrovascular perfusion disturbances.</p><p><strong>Interventions: </strong>The Fn concentration was determined using simple radial immunodiffusion.</p><p><strong>Results: </strong>The Fn concentration dropped significantly in all 12 patients (p < 0.01) in a dose-dependent manner beyond the dilution effect. 10% HES 200/0.62 caused a Fn decrease from 26.6 +/- 9.2 to 10.0 +/- 2.2 mg/dl (-62.2%), 6% HES reduced Fn from 25.5 +/- 9.9 to 15.0 +/- 3.2 mg/dl (-41.1%). In one patient there was a continuous decrease of Fn from 41.0 down to only 6.4 mg/dl.</p><p><strong>Conclusion: </strong>According to the results of animal experiments, the decrease of Fn seems to indicate depression of the RES. Besides its defense function, Fn probably plays a role in embryogenesis, wound healing, and blood clotting. Therefore, we assume that the drug-induced reduction of Fn possibly has clinical relevance.</p>","PeriodicalId":13632,"journal":{"name":"Infusionstherapie und Transfusionsmedizin","volume":"23 2","pages":"71-5"},"PeriodicalIF":0.0,"publicationDate":"1996-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000223261","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19750393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of two solutions with different glucose concentrations for infusion therapy during laparotomies in infants.","authors":"T H Fösel,&nbsp;M Uth,&nbsp;W Wilhelm,&nbsp;V Grüness","doi":"10.1159/000223263","DOIUrl":"https://doi.org/10.1159/000223263","url":null,"abstract":"<p><strong>Objective: </strong>Comparison of two commercially available solutions for intraoperative infusion therapy during laparotomies in infants using a standardized anesthetic technique (combination of general anesthesia with a caudal block).</p><p><strong>Design: </strong>Prospective, randomized.</p><p><strong>Setting: </strong>Infusion therapy during laparotomies in infants.</p><p><strong>Patients and methods: </strong>12 infants aged 1-12 weeks (group I) and 12 infants aged 5-14 months (group II) received at random either solution A with 2.5% glucose and 70 mmol Na+ or solution B with 5.5% glucose and 100 mmol Na+ at a rate of 8 ml/kg/h.</p><p><strong>Interventions: </strong>Central venous blood samples after induction of anesthesia and every 60 min for analysis of blood glucose, electrolyte, and hemoglobin concentrations. End of surgery: urine output during the operation and urine glucose and sodium concentrations. Statistical significance within the group: Friedmann Test, between the groups: U test by Wilcoxon, Mann and Witney.</p><p><strong>Significance: </strong>p < 0.05. RESULTS (given as median and range): In group I blood glucose concentrations rose significantly during surgery, however, there was no significant difference between group A or B after 1 h. A: 234 mg/dl (156-351) vs B: 239 mg/dl (166-329)) or 2 h: A: 254 mg/dl (166-331) vs B: 272 mg/dl (176-468). In group II blood glucose levels rose significantly during surgery, however, children of group B showed significantly higher blood glucose levels than group A after 1 h [A: 119 mg/dl (114-227), B: 203 mg/dl (162-238)], 2 h [A: 154 mg/ml (106-185), B: 284 mg/dl (243-317)] or 3 h [A: 159 mg/dl (116-218), B: 248 mg/dl (201-363)]. The plasma and urine sodium concentrations did statistically not differ between the two solutions.</p><p><strong>Conclusions: </strong>Solutions containing 5.5% glucose infused with 8 ml/kg/h caused in both age groups of infants intolerable hyperglycemias. In young infants, also a solution containing 2.5% glucose infused at a rate of 8 ml/kg/h leads to hyperglycemia, while in older children this amount of glucose is tolerated. It is recommended that for abdominal surgery in young infants glucose and fluid substitution is separated, in order to infuse glucose at an even lower rate. Still, blood glucose levels have to be monitored closely.</p>","PeriodicalId":13632,"journal":{"name":"Infusionstherapie und Transfusionsmedizin","volume":"23 2","pages":"80-4"},"PeriodicalIF":0.0,"publicationDate":"1996-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000223263","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19749070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Degree of patient education retardation preoperative autologous blood donation at a university clinic].","authors":"W Nussbaumer,&nbsp;W Mayer,&nbsp;D Schönitzer","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Uncovering the low degree of information in autologous blood donors for the purpose of implementation of corrective measures.</p><p><strong>Design: </strong>Questionnaire for autologous blood donors.</p><p><strong>Setting: </strong>Department for Transfusion Medicine of a University Clinic.</p><p><strong>Participants: </strong>174 autologous blood donors, selected by their responsible physician between June 1, 1995 and August 1, 1995.</p><p><strong>Results: </strong>64 (36.8%) of 174 patients who were admitted for withdrawal of autologous blood units had been informed by their treating physician, 100 (57.5%) of them came without any information and 10 (5.7%) on their own initiative. Of the 110 patients who had not been informed by their physician 16 declared to be sufficiently informed on risks or alternatives of allogeneic blood transfusion by mass media. Within the group of informed patients the percentage of those who did not fear allogeneic blood transfusions was clearly lower (23.4%) than within the group of uninformed patients (35.5%). Irrational fears were found less in informed than in uninformed patients (12.2% vs. 16.9%, informed vs. uninformed).</p><p><strong>Conclusions: </strong>Increasing numbers of patients are enrolled in allogeneic blood-saving programs, but still the degree of information does not seem to be sufficient. Because of the fact that information has to be given before the admission of the patient to the transfusion department, an enforced educational program on legal and medical issues of allogeneic blood transfusion for all medical disciplines involved is urgently required.</p>","PeriodicalId":13632,"journal":{"name":"Infusionstherapie und Transfusionsmedizin","volume":"23 2","pages":"67-70"},"PeriodicalIF":0.0,"publicationDate":"1996-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19750392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Fürst P, Stehle P: Glutamine supplemented nutrition in clinical practice--use of glutamine containing dipeptides].","authors":"A Baethmann","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13632,"journal":{"name":"Infusionstherapie und Transfusionsmedizin","volume":"23 2","pages":"98-9"},"PeriodicalIF":0.0,"publicationDate":"1996-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19749073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}